The structural basis for the specificity of epidermal growth factor and heregulin binding
about
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinaseNeuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampusStructural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificityBinding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesisThe cellular response to neuregulins is governed by complex interactions of the erbB receptor familyActivation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2The ErbB signaling network: receptor heterodimerization in development and cancerSelective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands.Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display.The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases.ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.Two EGF molecules contribute additively to stabilization of the EGFR dimerBivalence of EGF-like ligands drives the ErbB signaling networkThe C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligandsSensory and motor neuron-derived factor is a transmembrane heregulin that is expressed on the plasma membrane with the active domain exposed to the extracellular environment.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoEngineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyCombined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4.Glioma-specific antigens for immune tumor therapy.Synergistic regulation of Schwann cell proliferation by heregulin and forskolin.Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts.A Neu differentiation factor (NDF) domain essential for proliferation and alterations in morphology of colonic epithelial cells in vitro.Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation.Analysis of heregulin symmetry by weighted evolutionary tracing.Specificity within the EGF family/ErbB receptor family signaling network.HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.The hairpin stack fold, a novel protein architecture for a new family of protein growth factors.Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics.Phenotypic and Functional Characteristics of Human Schwann Cells as Revealed by Cell-Based Assays and RNA-SEQ.
P2860
Q22009917-5DE1506C-20AE-4303-878B-3DD33E7B58CFQ24336447-118841B0-08FA-40EA-8D5D-45DFF62273F3Q24645951-53F2E019-C8D2-4A12-9492-82B5B858C746Q27641695-83C95469-5BE2-4A33-9B46-BAF333921181Q28269163-EA4E88A4-0158-4473-8C7E-3A041CF722F4Q28609130-DF7022AC-6ACD-4A95-9BFE-9790C35B06C6Q28609160-F6FB57D2-BF02-45C0-9A1E-16C7260E48D4Q29617919-3184DDF2-14C2-4EFE-AAB1-9CB364A119A1Q30884331-12030C59-65A3-4866-B8D2-C3613727FD44Q32065974-7ECC7F2F-3341-4BFC-9965-4A4224EABF1CQ33538424-B1FAE069-F715-4BC8-8CE6-9E20522AE3B5Q33700160-CC52ECE2-3693-45F8-B128-C5FC3A7D4E7FQ33781099-1BF075F7-3F8B-4555-8247-007AE36FF908Q33885990-73B0727C-6C03-4712-A5F0-708549517CFBQ33887274-4FACDBEF-512A-453A-B774-CB078898764DQ33891080-7AD0A756-8518-4F50-8075-25F437B5ECE7Q34333631-59EDDE6E-8048-4FDB-B34F-DDB1C9FE6617Q34478797-15BEB48D-2457-46EA-8253-43DBF745C853Q34787422-EAF6E320-52ED-4403-A66F-CD3D5C36B6D5Q35145024-3DE14739-EA7D-48F1-AF9B-555B6C254503Q36116250-E2F57712-AAF1-4291-84DE-73B6CB62C71AQ36388501-9581BE1F-F04D-4322-886E-C873D7412B30Q36490427-3CCBBC59-BA58-48C0-B0B2-30A371E00432Q36690281-BA3AA157-D54C-4F77-9498-44E628296EA7Q39477214-863DCCF2-A34F-40E2-97C5-9A3A37DF83B1Q40221662-EEF8D941-6D61-41CB-BA8F-FCC0BEA77254Q40252778-42792731-5768-4D6A-A55D-D09A9289FCBDQ40339674-C586EA41-F0F2-49EF-8116-C99E0EA79913Q41014118-C3AC2378-D914-4DC8-B229-E90AB853EC53Q41039642-AA02F784-902B-4E75-BBE0-DD110C564C84Q41503493-9BB89923-02B1-459D-B12A-93F5232035F9Q41705578-84C4F2E9-04E1-4BE0-B51B-A3A74A872C2DQ41721612-D86F0392-5B18-4ADA-8A59-EBBA28C52D1CQ42288961-96EDBDFB-E7CB-4231-B2D1-9DB7FE838B07Q42637400-4C74A8A1-F9E2-4ED5-85ED-7B01706DB53BQ42657008-91DAEB48-23C5-4BF0-B13B-792CCDE318B4Q43844110-44A854F0-7660-4213-8014-7D9CE14DB5EFQ48140622-C9D3AFAD-61D4-4298-8EB0-E08A92B6BD01Q48256442-5E4D8493-6919-4A64-B13A-ADDCEC0471FD
P2860
The structural basis for the specificity of epidermal growth factor and heregulin binding
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
The structural basis for the specificity of epidermal growth factor and heregulin binding
@ast
The structural basis for the specificity of epidermal growth factor and heregulin binding
@en
The structural basis for the specificity of epidermal growth factor and heregulin binding
@nl
type
label
The structural basis for the specificity of epidermal growth factor and heregulin binding
@ast
The structural basis for the specificity of epidermal growth factor and heregulin binding
@en
The structural basis for the specificity of epidermal growth factor and heregulin binding
@nl
prefLabel
The structural basis for the specificity of epidermal growth factor and heregulin binding
@ast
The structural basis for the specificity of epidermal growth factor and heregulin binding
@en
The structural basis for the specificity of epidermal growth factor and heregulin binding
@nl
P2093
P2860
P356
P1476
The structural basis for the specificity of epidermal growth factor and heregulin binding
@en
P2093
B C Guarino
D H Singleton
E G Barbacci
G C Andrews
K J Rosnack
P2860
P304
P356
10.1074/JBC.270.16.9585
P407
P577
1995-04-21T00:00:00Z